¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Ciba Found Study Group"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® cohort study ÇÑ±Û °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
¼³¸í   
  ºÐ¼®¿ªÇп¡¼­ÀÇ ¿äÀÎ-´ëÁ¶¿¬±¸ÀÇ ÇÑ ±â¹ýÀÌ´Ù. »ç¶÷ÀÇ Áý´Ü¿¡¼­ Áúº´À¯Çà°ú °¡¼³¿äÀΰúÀÇ ¿¬°ü¼ºÀ» °íÂûÇÏ¿© Àΰú°ü°è¸¦ ¹àÈ÷´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÑ´Ù. °¡¼³¿äÀÎÀ» °®´Â Áý´Ü°ú °®Áö ¾Ê´Â Áý´Ü, È¤Àº ÀûÀº Áý´Ü°ú ¸¹Àº Áý´ÜÀÇ 2±º(ÄÚȣƮ)À¸·Î ³ª´©¾î ÃßÀû Á¶»çÇÏ¿© °¢ Áý´Ü¿¡¼­ÀÇ Áúº´ÀÇ ¹ß»ýºóµµ¸¦ ºñ±³Çϴ °ÍÀÌ´Ù. ÀϹÝÀûÀ¸·Î´Â ÀüÇâÀûÀΠ¿¬±¸·Î ÇàÇØÁö´Â °æ¿ì°¡ ¸¹À¸³ª ÈÄÇâÀûÀΠ¿¬±¸·Îµµ ÇàÇÏ¿©Áø´Ù.
¿µ¹® blood group ÇÑ±Û Ç÷¾×Çü
¼³¸í   
  »ç¶÷ÀÇ ÀûÇ÷±¸ Ç¥¸é¿¡´Â ¿©·¯ °¡Áö Ç׿ø¼ºÀ» °¡Áø ¹°ÁúÀÌ Á¸ÀçÇÑ´Ù. Á鿪ÇÐÀû ¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö Àִ ¹°ÁúÀ» Ç¥¸é¿¡ °¡Áö°í ÀÖ´Ù. ±×¸®°í »ç¶÷ÀÇ ÇǼӿ¡´Â À̰Ͱú ¹ÝÀÀÇÒ ¼ö°¡ Àִ Ç×üµµ Á¸ÀçÇÑ´Ù. »ç¶÷ÀÇ Ç÷¾×Àº À̰Ϳ¡ µû¶ó ¸î°¡Áö ÇüÀ¸·Î ºÐ·ùÇÒ ¼ö°¡ ÀÖ°í, À̰ÍÀ» Ç÷¾×ÇüÀ̶ó°í ÇÑ´Ù. Ç÷¾×ÇüÀº ÀûÇ÷±¸ Ç¥¸é¿¡ Àִ ¾î¶² ¹°ÁúÀ» ±âÁØÀ¸·Î ÇÏ´À³Ä¿¡ µû¶ó¼­ ¿©·¯ °¡Áö·Î ºÐ·ùµÉ ¼ö ÀÖ´Ù. ´ëÇ¥ÀûÀΠÇ÷¾×ÇüÀÇ ±¸ºÐ ¹æ¹ý¿¡´Â ABOÇ÷¾×Çü°ú RhÇ÷¾×ÇüÀÌ ÀÖ´Ù.
  
  1. ABO Ç÷¾×Çü
  
  °¡Àå ¸¹ÀÌ »ç¿ëµÇ°í Àִ Ç÷¾×Çü ±¸ºÐ¹ý. ÀûÇ÷±¸ Ç¥¸é¿¡´Â A, BÇüÀÇ µÎ °¡Áö ¹°ÁúÀ» Çϳª, È¤Àº µÑ, ¶Ç´Â Çϳªµµ °¡ÁöÁö ¾ÊÀ» ¼ö°¡ ÀÖ´Ù. ±×¸®°í ÇǼӿ¡´Â À̰Ͱú ¹ÝÀÀÇØ¼­ ÀûÇ÷±¸¸¦ ÆÄ±«Çϰųª ÀÀÁý½Ãų ¼ö Àִ ¹°Áú(Ç×ü)ÀÌ Á¸ÀçÇÑ´Ù. ¹°·Ð ÀÚ½ÅÀÇ ÀûÇ÷±¸°¡ °¡Áö°í Àִ ¹°Áú¿¡ ´ëÇÑ Ç×ü´Â Á¸ÀçÇÏÁö ¾Ê´Â´Ù.
  
  -AÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ AÇ׿ø, Ç÷¾×¼Ó¿¡ B¿¡ ´ëÇÑ Ç×ü
  
  -BÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ BÇ׿ø, Ç÷¾×¼Ó¿¡ A¿¡ ´ëÇÑ Ç×ü
  
  -ABÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ A, BÇ׿ø, Ç÷¾×¼Ó¿¡ A,B¿¡ ´ëÇÑ Ç×ü¸¦ °¡ÁöÁö ¾Ê´Â´Ù.
  
  -OÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ A, BÇ׿ø ¸ðµÎ¸¦ °¡ÁöÁö ¾Ê°í, Ç÷¾×¼Ó¿¡ A, B¿¡ ´ëÇÑ Ç׿øÀ» ¸ðµÎ °¡Áø´Ù.
  
  ´ë°³ À̰ÍÀ» ÀÌ¿ëÇÏ¿© ¼öÇ÷ÀǠŸ´ç¼º ¿©ºÎ¸¦ Á¶»çÇÑ´Ù. ¸¸¾à AÇü Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ÀÇ ÇǸ¦ BÇü Ç÷¾×ÇüÀÇ »ç¶÷¿¡°Ô ¼öÇ÷Çϸé BÇü Ç÷¾×ÇüÀ» °¡Áø ÀÚÀÇ ÇǼӿ¡ Àִ A¿¡ ´ëÇÑ Ç×ü¶§¹®¿¡ µé¾î¿Â AÇüÀÇ ÀûÇ÷±¸´Â ÆÄ±«µÇ°Å³ª, ÀÀÁýÀÌ µÈ´Ù. OÇüÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ÀÇ Ç÷¾×ÀÇ ÀûÇ÷±¸´Â Ç¥¸é¿¡ A, BÀÇ ¾î¶°ÇÑ ¹°Áúµµ °¡Áö°í ÀÖÁö ¾Ê¾Æ¼­ ¾î¶°ÇÑ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷¿¡°Ô ¼öÇ÷ÇØµµ ¹ÝÀÀÀ» ÀÏÀ¸Å°Áö ¾Ê´Â´Ù. À̿͠°°Àº ¿ø¸®·Î ABÇüÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷Àº Ç÷¾×¼Ó¿¡ A, B¿¡ ´ëÇÑ Ç×ü¸¦ ¸ðµÎ °¡Áö°í ÀÖÁö ¾ÊÀ¸¹Ç·Î ¾î¶°ÇÑ Ç÷¾×ÇüÀ̶󵵠¹ÞÀ» ¼ö°¡ ÀÖ´Ù.
  
  2. RhÇ÷¾×Çü
  
  ÀûÇ÷±¸Ç¥¸é¿¡ Àִ D¶ó´Â ¹°ÁúÀ» ±âÁØÀ¸·Î ÇÏ¿© Ç÷¾×ÇüÀ» ³ª´©´Â ¹æ¹ý. ¸¸¾à D¶ó´Â ¹°ÁúÀÌ ÀûÇ÷±¸ÀǠǥ¸é¿¡ Á¸ÀçÇϸé Rh(+), Á¸ÀçÇÏÁö ¾ÊÀ¸¸é Rh(£­)¶ó°í ÇÑ´Ù. ABOÇ÷¾×Çü¿¡¼­¿Í °°ÀÌ Rh(+)Ç÷¾×ÇüÀ» °¡Áö´Â »ç¶÷ÀÇ ÇǼӿ¡´Â D¶ó´Â ¹°Áú¿¡ ´ëÇÑ Ç×ü°¡ Á¸ÀçÇÏÁö ¾ÊÁö¸¸ Rh(£­)Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ÀÇ ÇǼӿ¡´Â D¿¡ ´ëÇÑ Ç×ü°¡ Á¸ÀçÇÑ´Ù. ABOÇ÷¾×Çü°ú ¸¶Âù°¡Áö·Î ¼öÇ÷ÀǠŸ´ç¼ºÀ» °áÁ¤Çϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • air study
    °ø±âÁÖÀÔ°Ë»ç
  • cohort study
    ÄÚȣƮ¿¬±¸, ÄÚȣƮÁ¶»ç
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • crossover study
    ±³Â÷¿¬±¸
  • cross-sectional study
    ´Ü¸é¿¬±¸
  • case comparison study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case referent study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case study
    Áõ·Ê¿¬±¸, »ç·ÊÁ¶»ç
  • case-control study
    ȯÀÚ´ëÁ¶±º¿¬±¸, »ç·Ê´ëÁ¶±º¿¬±¸
  • diachronic study
    ºñµ¿½Ã¿¬±¸
  • double blind study
    ÀÌÁ߸Ͱ˿¬±¸
  • ecological study
    »ýÅ¿¬±¸
  • feasibility study
    °¡´É¼º¿¬±¸
  • follow-up study
    ÃßÀûÁ¶»ç
  • family study
    °¡Á·Á¶»ç
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • group
    ¹«¸®, ±º, Áý´Ü, ¸ðµÒ
  • amino group
    ¾Æ¹Ì³ë±â
  • diagnosis related group
    Æ÷°ý¼ö°¡Á¦
  • high risk group
    °íÀ§Ç豺
  • low risk group
    ÀúÀ§Ç豺
  • self-help group
    ÀÚ°¡µµ¿òÁý´Ü
  • group practice
    Áý´Ü°³¾÷
  • blood group system
    Ç÷¾×Çü±º
  • study design
    ¿¬±¸¼³°è
  • study
    ¿¬±¸, °Ë»ç, Á¶»ç
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • case-control study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • cohort study
    ÄÚȣƮ¿¬±¸
  • cross-sectional study
    ´Ü¸éÁ¶»ç¿¬±¸
  • ecological study
    »ýÅ¿¬±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • air study
    °ø±âÁÖÀÔ°Ë»ç
  • arterial blood gas study
    µ¿¸ÆÇ÷°¡½ººÐ¼®
  • cardiac gated MR study
    ½ÉÀ嵿±âÀÚ±â°ø¸í°Ë»ç
  • case study
    Áõ·Ê¿¬±¸
  • case comparison study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case compeer study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case referent study
    ȯÀÚ´ëÁ¶±º¿¬±¸
  • case-base study
    ȯÀÚ¸ðÁý´Ü¿¬±¸
  • case-control study
    (¢¡retrospective) ÈÄÇ⿬±¸, µÞ¹æÇ⿬±¸
  • cohort study
    (¢¡prospective) °èȹ¿¬±¸, ÀüÇ⿬±¸, ¾Õ¹æÇ⿬±¸
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • cross-sectional study
    ´Ü¸éÁ¶»ç¿¬±¸
  • double-blind study
    ÀÌÁ߸Ͱ˹ý
  • study design
    ¿¬±¸°èȹ
  • family study
    °¡Á·Á¶»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • B cell study
    B ¼¼Æ÷°Ë»ç
  • air study
    °ø±â(ÁÖÀÔ) °Ë»ç(¹ý)
  • arterial blood gas study
    µ¿¸ÆÇ÷ °¡½ººÐ¼®
  • infection control study
    °¨¿°°ü¸®¿¬±¸
  • phase 1 study
    ÀÓ»óÁ¦1»ó½ÃÇè.
  • pilot study
    ¿¹ºñ½ÇÇè.
  • population study
    Àα¸Á¶»ç
  • preclinical study
    ÀüÀÓ»ó½ÃÇè(îñìúßÉãËúÐ).
  • pressure flow study
    ¾Ð·ù·® Á¶»ç
  • pressure-perfusion study
    ¾Ð·Â°ü·ù°Ë»ç
  • prospective study
    °èȹÀû¿¬±¸, ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£ °Ë»ç
  • ABO blood group
    ABO Ç÷¾×Çü.
  • ABO blood group system
    ABOÇ÷¾×Çü°è(Åë).
  • ABO blood group=ABO system
    ABO Ç÷¾×Çü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • air study
    °ø±â(ÁÖÀÔ) °Ë»ç(¹ý)
  • arterial blood gas study
    µ¿¸ÆÇ÷ °¡½ººÐ¼®
  • cardiac gated MR study
    ½ÉÀ嵿±â ÀÚ±â°ø¸í °Ë»ç
  • case control study
    ȯÀÚ´ëÁ¶¿¬±¸.
  • case study
    Áõ·Ê¿¬±¸(Áõ¿¹¿¬±¸).
  • case study
    Áõ·Ê¿¬±¸(ñøçÓæÚϼ).
  • cohort study
    ÄÚ¿ÀÆ®¿¬±¸(ÊÙËçË´), Æø·ÎºñÆø·Î¿¬±¸.
  • controlled clinical study
    (Ãß°èÇÐÀû) °ü¸®È­(Ì§Ë­Ì°ËøË´ËöÌ´)(ÀÓ»ó)½ÃÇè( ËöË×ËàÌ´).
  • double-blind study
    ÀÌÁ߸ͰË.
  • family study
    °¡Á·Á¶»ç(¿¬±¸)
  • first pass study
    ÀÏÂ÷Åë°ú°Ë»ç.
  • follow-up study
    ÃßÀûÁ¶»ç
  • infection control study
    °¨¿°°ü¸®¿¬±¸
  • microbiologic study
    ¹Ì»ý¹°ÇÐÀû °Ë»ç
  • molecular genetic study
    ºÐÀÚÀ¯ÀüÇÐ<ÀÚ>°Ë»ç
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Group of isogenous chondrocyte
    ¿¬°ñ¼¼Æ÷¹«¸®
    [¿¾ ¿ë¾î] ¿¬°ñ¼¼Æ÷±ºÁý
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • end group spine
    ±ê³¡°¡½Ã
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • blance study
    ±ÕÇü¿¬±¸(гû¬æÚϼ)
  • ABO blood group (type) system
    ABOÇ÷¾×Çü (úìäûúþ) ½Ã½ºÅÛ
  • acetyl group
    ¾Æ¼¼Æ¿±â(Ðñ)
  • acyl group
    ¾Æ½Ç±â(Ðñ)
  • alcoholic hydroxyl group
    ¾ËÄݼº(àõ) ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • aldehyde group
    ¾Ëµ¥ÇÏÀ̵å±â(Ðñ)
  • amino group
    ¾Æ¹Ì³ë±â(Ðñ)
  • angle methyl group
    ¾Þ±Û¸ÞÆ¿±â(Ðñ)
  • aryl group
    ¾Æ¸±±â(Ðñ)
  • azide group
    ¾ÆÀÚÀ̵å±â(Ðñ)
  • azo group
    ¾ÆÁ¶±â(Ðñ)
  • bathochromic group
    ÀåÆÄ»ö´Ü±º(íþ÷îßäÓ¥ÏØ)
  • blocking group
    Â÷´Ü±â(ó´Ó¨Ðñ)
  • carbamoyl group
    Ä«¸£¹Ù¸ðÀÏ ±â(Ðñ)
  • carbonyl group
    Ä«¸£º¸´Ò±â(Ðñ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • control group
    ´ëÁ¶±º
  • group file
    ±×·ì È­ÀÏ
  • high risk group
    °íÀ§Çèµµ±º
  • JPEG [=joint photographic expert group]
    JPEG
  • air study
    °ø±â(ÁÖÀÔ)°Ë»ç(¹ý)
  • cardiac gated MR study
    ½ÉÀ嵿±âÀÚ±â°ø¸í°Ë»ç
  • pilot study
    ¿¹ºñ½ÇÇè
  • prospective study
    ÀüÇâÀû¿¬±¸
  • real time study
    ½Ç½Ã°£°Ë»ç
  • retrospective study
    ÈÄÇ⼺¿¬±¸
  • study of choice
    ÃÖ¼±ÀÇ °Ë»ç
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CCG Children's Cancer Study Group; cholecystogram, cholecystography; clinically coherent group
LD1 isoenzyme of lactate dehydrogenase found in the heart, erythrocytes, and kidneys
LD2 isoenzyme of lactate dehydrogenase found in the lungs
LD3 isoenzyme of lactate dehydrogenase found in the lungs
LD4 isoenzyme of lactate dehydrogenase found in the liver
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
UNICEF United Nations Children's Found
Study 1 study
Study 2 study
Study A study
Study B study
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • JrId: 2949
    JournalTitle: Ciba Foundation study group.
    MedAbbr: Ciba Found Study Group
    ISSN: 0069-4037
    ESSN:
    IsoAbbr:
    NlmId: 373160
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ABO blood group system
    ABO Ç÷¾×Çü°è, ABO Ç÷¾×Çü °èÅë
    A, B´Â ¿ì¼º, O´Â ¿­¼ºÀ¸·Î¼­, A, B, AB, OÇüÀÌ ÀÖ´Ù.
  • allyl group
    ¾Ë¸±±º
  • axon group
    Ãà»è ±º
  • blood group
    Ç÷¾×Çü
    µ¿ÀǾî=blood ty
  • blood group incompatibility
    Ç÷¾×Çü ºÎÀûÇÕ
  • borderline group
    °æ°è ±º
  • chloramphenicol group antibiotics
    Ŭ·Î¶÷Æä´ÏÄݱº Ç×»ýÁ¦
  • coxsackie group A virus
    ÄÛ»èŰ A±º ¹ÙÀÌ·¯½º
    ¼öÆ÷¼º º´º¯ÀÎ Æ÷Áø¼º ±¸Çù¿°À» ¹ß»ý ½ÃŲ´Ù.
  • Coxsackie virus group A
    A±º ÄÛ»çŰ ¹ÙÀÌ·¯½º
  • E-blood group
    ÀÌ½Ä Ç÷¾×Çü
    »ç¶÷ÀÇ Ç÷¾×ÇüÀÇ Çϳª. OÇü ÀÌ¿ÜÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ Áß¿¡¼­ ¹ìÀå¾îÀÇ Ç÷û ¼Ó¿¡ Á¸ÀçÇÏ´Â ÀÀÁý¼Ò¿¡ °­ÇÏ°Ô ¹ÝÀÀÇÏ´Â °ÍÀ» EÇü, ¹ÝÀÀÀÌ ¾àÇÑ °ÍÀ» eÇüÀ¸·Î ÇÏ´Â Ç÷¾×ÇüÀ» ¸»ÇÑ´Ù. EÇüÀº ABO½ÄÀÇ BÇü¿¡ °¡Àå ¸¹°í, A, AB ¼øÀ¸·Î ºóµµ°¡ ³·´Ù. ¶ÇÇÑ À¯ÀüÀÚÇü°úµµ °ü°è°¡ ÀÖÀ¸¸ç II, II
  • herpes group of virus
    Æ÷Áø¼º ¹ÙÀÌ·¯½º
  • high risk group
    °íÀ§Çèµµ±º
  • Lutheran blood group
    ·çÅ×¶õ½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ ÀÏÁ¾. ¿ì¿­ÀÌ ¾ø´Â ÇÑ ½ÖÀÇ ´ë¸³ À¯ÀüÀÚ Lu, Lu¿¡ ÀÇÇØ¼­ Áö¹èµÇ°í, ÀÌ À¯ÀüÀÚÀÇ Á¶ÇÕ¿¡ µû¶ó¼­ »ç¶÷ÀÇ Ç÷±¸´Â Lu
  • methyl green-pyronin of nucleolus

    methyl group

    ¸ÞÄ¥±â
  • myelinated group
    À¯¼öÃʱº
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
analytic study In epidemiology, a study designed to examine associations, commonly putative or hypothesised causal relationships; usually concerned with identifying or measuring the effects of risk factors or with the health effects of specific exposures.
(05 Mar 2000)
blinded study Clinical trials of drugs are often done blinded so that the patient does not know (is blinded as to) whether they are receiving the product being tested or the control/placebo to ensure that the results of a study are not affected by a possible placebo effect (by the power of suggestion).
(12 Dec 1998)
blind study A study in which the experimenter is unaware of which group is subject to which procedure.
(05 Mar 2000)
case-control study <epidemiology> A study in which the risk factors of people with a disease are compared with those without a disease.
It is an epidemiological method that begins by identifying persons with the disease or condition of interest (the cases) and compares their past history of exposure to identified or suspected risk factors with the past history of similar exposures among persons who resemble the cases but do not have the disease or condition of interest (the controls).
The relationship of an attribute to the disease can therefore be examined by comparing affected and non-affected individuals with regard to the frequency or levels of the attribute in each group.
(05 May 2002)
retrospective study <epidemiology> A study in which people are enrolled and then have their history of risks, infections or disease measured.
(05 Dec 1998)
rosenzweig picture-frustration study A projective test depicting cartoon-like characters in frustrating situations. The scoring of the subject's responses indicates the direction of hostility or aggression, that is, whether he blames himself, the other person, or the set of circumstances.
(12 Dec 1998)
cohort study A study using epidemiological methods, such as a clinical trial, in which a cohort with a particular attribute (e.g., smokers, recipients of a drug) is followed prospectively and compared for some outcome (e.g., disease, cure) with another cohort not possessing the attribute.
(05 Mar 2000)
pioped study <radiology> 251 patients with documented PE on pulmonary angiograms were given V/Q scans: 102 high probability, 105 intermediate probability, 39 low probability, 5 normal or near-normal
(12 Dec 1998)
multicenter study A controlled study executed by several cooperating institutions.
(12 Dec 1998)
multigeneration study Toxicity test in which at least 3 generations of the test organisms are exposed to the substance being assessed. Exposure is usually continuous.
Any medical study which follows a family of people through several generations.
(09 Oct 1997)
crossover study <statistics> A study that compares two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. Usually refers to a study in which the subject is switched from the experimental to the control procedure (or vice versa).
In the case of two treatments, a and b, half the subjects are randomly allocated to receive these in the order a, b and half to receive them in the order b, a.
A criticism of this design is that effects of the first treatment may carry over into the period when the second is given.
With this type of study, every patient serves as his or her own control.
(21 Jun 2000)
cross-sectional study <epidemiology> A study in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with longitudinal studies which are followed over a period of time.
Synonym: horizontal study.
(18 Jul 2002)
preclinical study A study to test a drug, procedure or other medical treatment in animals. The aim is to collect data in support of safety. Preclinical studies are required before clinical trials can be started.
(12 Dec 1998)
prospective study <epidemiology> A study in which people are initially enrolled and then followed up at subsequent times.
(05 Dec 1998)
study 1. To apply the mind to; to read and examine for the purpose of learning and understanding; as, to study law or theology; to study languages.
2. To consider attentively; to examine closely; as, to study the work of nature. "Study thyself; what rank or what degree The wise Creator has ordained for thee." (Dryden)
3. To form or arrange by previous thought; to con over, as in committing to memory; as, to study a speech.
4. To make an object of study; to aim at sedulously; to devote one's thoughts to; as, to study the welfare of others; to study variety in composition. "For their heart studieth destruction." (Prov. Xxiv. 2)
Origin: OE. Studie, L. Studium, akin to studere to study; possibly akin to Gr. Haste, zeal, to hasten; cf. OF. Estudie, estude, F. Etude. Cf. Etude, Student, Studio, Study, v. I.
1. A setting of the mind or thoughts upon a subject; hence, application of mind to books, arts, or science, or to any subject, for the purpose of acquiring knowledge. "Hammond . . . Spent thirteen hours of the day in study." (Bp. Fell) "Study gives strength to the mind; conversation, grace." (Sir W. Temple)
2. Mental occupation; absorbed or thoughtful attention; meditation; contemplation. "Just men they seemed, and all their study bent To worship God aright, and know his works." (Milton)
3. Any particular branch of learning that is studied; any object of attentive consideration. "The Holy Scriptures, especially the new Testament, are her daily study." (Law) "The proper study of mankind is man." (Pope)
4. A building or apartment devoted to study or to literary work. "His cheery little study."
5. A representation or rendering of any object or scene intended, not for exhibition as an original work of art, but for the information, instruction, or assistance of the maker; as, a study of heads or of hands for a figure picture.
6. A piece for special practice. See Etude.
Source: Websters Dictionary
(01 Mar 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • found
    â¼³ÇÏ´Ù,-ÀÇ ±âÃʸ¦ µÎ´Ù
  • found
    FINDÀÇ °ú°Å;°ú°ÅºÐ»ç;(¹æ,¹è µîÀÌ) ¼³ºñ¸¦ °®Ãá;Áö½Ä;±³¾çÀÌ ÀÖ´Â;(±Þ·á ÀÌ¿ÜÀÇ ¹«·á Á¦°øÀÇ) ¼÷½Ä
  • found
    ±âÃʸ¦ µÎ´Ù;±Ù°Å·ÎÇÏ´Ù;â¼³ÀÚ;½ÃÁ¶;ÁÖÁ¶ÇÏ´Ù;¼³¸³ÇÏ´Ù;...¿¡ ±Ù°ÅÇÏ´Ù
  • found
    (±Ý¼ÓÀ») ³ìÀÌ´Ù;³ì¿© º×´Ù;ÁÖÁ¶ÇÏ´Ù;(À¯¸® Á¦Ç°À») ¸¸µé´Ù
  • found art
    ÆÄ¿îµå ¾ÆÆ®(½¬¸£·¹¾Ë¸®½¿¿¡¼­ ÁÖÀåµÇ´Â ¿¹¼ú) )
  • found object
    =OBJET TROUVE
  • new found
    »õ·Î ¹ß°ßµÈ
  • study
    °øºÎ,¼­Àç,Çаú,¹è¿ì´Ù,¿¬±¸ÇÏ´Ù
  • brown study
    ¸ÛÇÏ´Ï»ý°¢¿¡Àá±è
  • case study
    »ç·Ê¿¬±¸;ÄÉÀ̽º ½ºÅ͵ð M
  • desk study
    (¿µ)Ź»ó ¿¬±¸
  • feasibility study
    Ÿ´ç¼º Á¶»ç;¿¹ºñ Á¶»ç
  • field study
    =FIELDWORK
  • home study
    (Åë½Å ±³À°¿¡¼­ÀÇ)ÀÚÅà ÇнÀ;(¹Ì)(¾çºÎ¸ð·Î¼­ÀÇ ÀûºÎ¸¦ ¾Ë¾Æº¸´Â)°¡Á¤Á¶»ç
  • home study
    Åë½Å±³À°
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á